Incyte and Merck Push I/O Drug Forward
This article was originally published in Scrip
You may also be interested in...
Expansion of 2015 development partnership adds lung and bladder cancer as well as renal and head-and-neck carcinoma to trials of the two immuno-oncology drugs. Jazz licenses Japanese rights to two of its commercial products to Nippon Shinyaku.
Doesn't every biopharma company have an immuno-oncology strategy these days? It certainly seems that way, considering the number of drug developers that are labeling their therapeutic candidates as immunotherapies regardless of whether the description truly fits their asset.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.